Supernus Pharmaceuticals Inc
SUPN45.799USD
+0.999+2.23%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
2.57BCap. mercado
39.85P/E TTM
Más Datos de Supernus Pharmaceuticals Inc Compañía
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
Información de la empresa
Símbolo de cotizaciónSUPN
Nombre de la empresaSupernus Pharmaceuticals Inc
Fecha de salida a bolsaDec 28, 2010
Director ejecutivoMr. Jack A. Khattar
Número de empleados674
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 28
Dirección9715 Key West Avenue
CiudadROCKVILLE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal20850
Teléfono13018382500
Sitio Webhttps://www.supernus.com
Símbolo de cotizaciónSUPN
Fecha de salida a bolsaDec 28, 2010
Director ejecutivoMr. Jack A. Khattar
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.12M
+0.92%
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
46.31K
-13.87%
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Chief Operating Officer, Chief Technology Officer
Chief Operating Officer, Chief Technology Officer
15.15K
--
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
13.37K
+5.27%
Dr. Jonathan Rubin, M.D.
Dr. Jonathan Rubin, M.D.
Senior Vice President, Chief Medical Officer - Research and Development
Senior Vice President, Chief Medical Officer - Research and Development
9.63K
+8.32%
Mr. Timothy C. (Tim) Dec, CPA
Mr. Timothy C. (Tim) Dec, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
901.00
-92.89%
Mr. Charles W. Newhall, III
Mr. Charles W. Newhall, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Bethany L. Sensenig
Ms. Bethany L. Sensenig
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.12M
+0.92%
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
46.31K
-13.87%
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Chief Operating Officer, Chief Technology Officer
Chief Operating Officer, Chief Technology Officer
15.15K
--
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
13.37K
+5.27%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Net product sales-Qelbree
64.75M
43.21%
Net product sales - GOCOVRI
30.69M
20.48%
Net product sales-APOKYN
14.98M
10.00%
Net product sales- Trokendi XR
12.80M
8.54%
Net product sales- Oxtellar XR
10.20M
6.81%
Otro
16.41M
10.96%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
149.82M
100.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Net product sales-Qelbree
64.75M
43.21%
Net product sales - GOCOVRI
30.69M
20.48%
Net product sales-APOKYN
14.98M
10.00%
Net product sales- Trokendi XR
12.80M
8.54%
Net product sales- Oxtellar XR
10.20M
6.81%
Otro
16.41M
10.96%
Estadísticas de accionistas
Actualizado: vie., 15 de ago
Actualizado: vie., 15 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
14.29%
The Vanguard Group, Inc.
11.04%
Armistice Capital LLC
8.58%
Dimensional Fund Advisors, L.P.
5.39%
Macquarie Investment Management
4.93%
Otro
55.77%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
14.29%
The Vanguard Group, Inc.
11.04%
Armistice Capital LLC
8.58%
Dimensional Fund Advisors, L.P.
5.39%
Macquarie Investment Management
4.93%
Otro
55.77%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
55.47%
Investment Advisor/Hedge Fund
29.99%
Hedge Fund
17.53%
Individual Investor
4.23%
Research Firm
2.61%
Pension Fund
1.62%
Venture Capital
1.50%
Bank and Trust
0.70%
Sovereign Wealth Fund
0.10%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
565
63.61M
113.46%
-2.51M
2025Q1
587
64.77M
115.71%
-2.86M
2024Q4
569
65.17M
116.92%
-2.59M
2024Q3
551
65.02M
117.72%
-2.14M
2024Q2
536
63.49M
115.33%
-2.27M
2024Q1
535
61.47M
111.83%
-3.83M
2023Q4
534
61.60M
112.54%
-3.30M
2023Q3
534
60.88M
111.42%
-4.46M
2023Q2
534
61.11M
111.93%
-1.60M
2023Q1
539
59.34M
108.94%
-3.56M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
8.20M
14.65%
-297.23K
-3.50%
Mar 31, 2025
The Vanguard Group, Inc.
6.15M
10.99%
+13.13K
+0.21%
Mar 31, 2025
Armistice Capital LLC
5.20M
9.28%
+360.00K
+7.44%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.90M
5.19%
+25.18K
+0.87%
Mar 31, 2025
Macquarie Investment Management
2.70M
4.82%
+70.76K
+2.69%
Mar 31, 2025
State Street Global Advisors (US)
2.15M
3.83%
-42.85K
-1.96%
Mar 31, 2025
Khattar (Jack A)
2.01M
3.6%
--
--
Apr 22, 2025
Renaissance Technologies LLC
1.59M
2.83%
-13.00K
-0.81%
Mar 31, 2025
Stephens Investment Management Group, LLC
1.74M
3.1%
-13.59K
-0.78%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.33M
2.37%
-183.95K
-12.18%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
